Increased risk of myocardial infarction with PPIs?

Increased risk of myocardial infarction with PPIs? Reactions 1680, p9 - 2 Dec 2017 Increased risk of myocardial infarction with PPIs? There is no evidence that prescribing proton pump inhibitors (PPIs) increases the risk of myocardial infarction (MI) compared with prescribing histamine-2 receptor antagonists (H2RAs), according to study results reported in Gastroenterology, and "physicians and patients should not avoid starting a PPI because of concerns related to MI risk". The observational cohort study used the US Truven Health Analytics MarketScan Research Database. Claims from eligible adults who started new prescriptions for PPIs or H2RAs in 2001–2014 were identified. The Commercial Claims and Encounters database included 3675 120 patients who received PPIs and 829 441 patients who received H2RAs, while the Medicare Supplemental database identified 894 821 patients who received PPIs and 192 607 patients who received H2RAs. The primary outcome was hospitalised MI. In the commercial claims cohort, the crude MI risk increased over the time of the study. The 3-month risk for PPI compared with H2RA recipients was "essentially null," note the authors (weighted risk ratio [RR] 1.00; 95% CI 0.87, 1.16), and remained approximately null for other timepoints. At 12 months, there was a slight but insignificantly decreased risk of MI per 1000 PPI recipients (weighted risk difference [RD] –0.08; –0.51, 0.36). This had reversed by 36 months (RD 1.21; 1.07, 1.37). Similarly, the MI risk increased over time in the Medicare Supplemental cohort; the mean as-treated follow-up duration was longer for PPI compared with H2RA recipients (241 vs 147 days). Relative risks were different at 3 months (RR 0.87; 0.76, 0.99) and 12 months (RR 0.99; 0.84, 1.17). There were small risk differences per 1000 patients between 3 months (RD –0.35; –0.72, –0.02) and 12 months (RD –0.33; –4.40, 3.46). The authors conclude that "for U.S. patients enrolled in privately insured plans with no previous history of MI, prescription PPI utilization does not appear to pose a short-term risk for MI over the utilization of prescription H2RAs, a drug similarly recommended to treat gastrointestinal conditions like GERD". Landi SN, et al. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). Gastroenterology : 6 Nov 2017. Available from: URL: http://doi.org/10.1053/j.gastro.2017.10.042 803284961 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Increased risk of myocardial infarction with PPIs?

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/increased-risk-of-myocardial-infarction-with-ppis-pSXQ68xc0n
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38940-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p9 - 2 Dec 2017 Increased risk of myocardial infarction with PPIs? There is no evidence that prescribing proton pump inhibitors (PPIs) increases the risk of myocardial infarction (MI) compared with prescribing histamine-2 receptor antagonists (H2RAs), according to study results reported in Gastroenterology, and "physicians and patients should not avoid starting a PPI because of concerns related to MI risk". The observational cohort study used the US Truven Health Analytics MarketScan Research Database. Claims from eligible adults who started new prescriptions for PPIs or H2RAs in 2001–2014 were identified. The Commercial Claims and Encounters database included 3675 120 patients who received PPIs and 829 441 patients who received H2RAs, while the Medicare Supplemental database identified 894 821 patients who received PPIs and 192 607 patients who received H2RAs. The primary outcome was hospitalised MI. In the commercial claims cohort, the crude MI risk increased over the time of the study. The 3-month risk for PPI compared with H2RA recipients was "essentially null," note the authors (weighted risk ratio [RR] 1.00; 95% CI 0.87, 1.16), and remained approximately null for other timepoints. At 12 months, there was a slight but insignificantly decreased risk of MI per 1000 PPI recipients (weighted risk difference [RD] –0.08; –0.51, 0.36). This had reversed by 36 months (RD 1.21; 1.07, 1.37). Similarly, the MI risk increased over time in the Medicare Supplemental cohort; the mean as-treated follow-up duration was longer for PPI compared with H2RA recipients (241 vs 147 days). Relative risks were different at 3 months (RR 0.87; 0.76, 0.99) and 12 months (RR 0.99; 0.84, 1.17). There were small risk differences per 1000 patients between 3 months (RD –0.35; –0.72, –0.02) and 12 months (RD –0.33; –4.40, 3.46). The authors conclude that "for U.S. patients enrolled in privately insured plans with no previous history of MI, prescription PPI utilization does not appear to pose a short-term risk for MI over the utilization of prescription H2RAs, a drug similarly recommended to treat gastrointestinal conditions like GERD". Landi SN, et al. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). Gastroenterology : 6 Nov 2017. Available from: URL: http://doi.org/10.1053/j.gastro.2017.10.042 803284961 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial